You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Indication1

Bexsero is indicated for active immunisation of individuals from 2 months of age and older against invasive meningococcal disease caused by Neisseria meningitidis group B.

 

Dosage1

Bexsero is available as a white opalescent liquid suspension for injection in a pre-filled syringe and comes as a 0.5 ml dose.

Bexsero offers several schedule options with flexible dosing intervals, making it simple to fit with routine vaccination visits1

Bexsero Overview

The use of this vaccine should be in line with official recommendations

Coadministration:

Bexsero can be given concomitantly with any of the following vaccine antigens, either as monovalent or as combination vaccines1:

— Meningococcal group C-CRM conjugate

— Diphtheria, tetanus, acellular pertussis, inactivated polio

Haemophilus influenzae type b

— Hepatitis B

— Heptavalent pneumococcal conjugate

— Measles, mumps, rubella

— Varicella

Bexsero is the only MenB vaccine that can be coadministered with meningococcal group C-CRM conjugate and Haemophilus influenzae type b1,2

Storage and stability1

  • Shelf life: 3 years
  • Store in a refrigerator (2°C–8°C)
  • Do not freeze
  • Store in the original package in order to protect from light
  • Upon storage, a fine off-white deposit may be observed in the prefilled syringe containing the suspension
  • Before use, the pre-filled syringe should be well shaken in order to form a homogeneous suspension.
     

Link to resources

References:

  1. Bexsero Summary of Product Characteristics. Available from:https://www.medicines.ie/medicines/bexsero-suspension-for-injection-in-pre-filled-syringe-31445/ Last accessed – November 2018
  2. Trumenba Summary of Product Characteristics. Available from: https://www.medicines.ie/medicines/trumenba-34065/ Last accessed – November 2018
  3. HSE Immunisation Guidelines. Available from: https://www.hse.ie/eng/health/immunisation/hcpinfo/guidelines/chapter13.pdf, accessed: November 2018

Adverse events should be reported to the Health Products Regulatory Authority (HPRA) using an Adverse Reaction Report Form obtained either from the HPRA or electronically via the website at www.hpra.ie. Adverse reactions can also be reported to the HPRA by calling: (01) 6764971. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

Bexsero is a registered trademark of the GlaxoSmithKline Group of Companies